PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）

Abroad (travel likely)RecruitingPHASE4

Conditions

Hemophilia · Inhibitors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of haematology and Blood diseases hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Mankai Ju) · jumankai@ihcams.ac.cn · +8615620988690
Contact: Study coordinator (Lei Zhang) · zhanglei1@ihcams.ac.cn · 2223608177

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Hemophilia A Research Program

Hemophilia A · Hemophilia A, Severe · Factor VIII (FVIII)

Abroad (travel likely)Recruiting

Seattle, United States

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Hemophilia A

Abroad (travel likely)RecruitingPHASE4

Zagreb, Croatia · Brno, Czechia

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Hemophilia A With Inhibitor · Hemophilia B With Inhibitor

Abroad (travel likely)RecruitingPHASE4

Phoenix, United States · Little Rock, United States

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

Abroad (travel likely)RecruitingPHASE4

Tianjin, China